Log in to save to my catalogue

The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Result...

The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Result...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_1927973172

The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models

About this item

Full title

The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models

Publisher

United States: Public Library of Science

Journal title

PloS one, 2017-08, Vol.12 (8), p.e0182852-e0182852

Language

English

Formats

Publication information

Publisher

United States: Public Library of Science

Subjects

Subjects and topics

More information

Scope and Contents

Contents

The therapeutic options for metastatic neuroendocrine tumors (NETs) are limited. As PI3K signaling is often activated in NETs, we have assessed the effects of selective PI3Kp110α inhibition by the novel agent BYL719 on cell viability, colony formation, apoptosis, cell cycle, signaling pathways, differentiation and secretion in pancreatic (BON-1, QG...

Alternative Titles

Full title

The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_plos_journals_1927973172

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_1927973172

Other Identifiers

ISSN

1932-6203

E-ISSN

1932-6203

DOI

10.1371/journal.pone.0182852

How to access this item